PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with ...
Do carro ao voto, da lei ao conto, da notícia à crítica. Entenda tudo que é preciso saber.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback